MorphoSys

The page presents the Novartis global product portfolio and information about pharmaceutical treatments.

Novartis said the FDA granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgAN at risk of progression. It received accelerated approval in August 2024 to reduce proteinuria.

The page provides Novartis multimedia resources.

News and more from the frontiers of medicine.

The page includes recent and past Novartis healthcare news, including media releases and featured information.

The page provides tips and insights to help with applications.

The page lists opportunities with Novartis and directs applicants to GTx Career Search for roles with Novartis Gene Therapies, formerly AveXis.

The page lists careers at Novartis and describes its teams as diverse and inclusive.

The Novartis Board of Directors is responsible for the direction, strategy, and administration of the company.

Under the leadership of Vasant Narasimhan, the Executive Committee of Novartis (ECN) is responsible for overseeing the company's business operations.

Ensuring people everywhere can benefit from the latest medical breakthroughs is a shared global responsibility.

Novartis says it does not take shortcuts in innovation.

The company’s medicines combine science with an understanding of the human experience of disease.

Novartis says it has pursued scientific breakthroughs for more than 250 years, including 30 years as Novartis, and turns healthcare innovations into medicines for patients.

The Novartis Privacy Hub is the entry page for all information regarding data privacy at Novartis.